Preventing, Treating Relapse After ASCT in Hematologic Malignancy Patients

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation.

In this video, Robert J. Soiffer, MD, of the Dana-Farber Cancer Institute in Boston, highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation (ASCT).

Soiffer gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Related Videos
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma

April 12th 2024
Article

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study

Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study

March 27th 2024
Article

Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

Evaluating Secondary Primary Malignancy Risk After CAR T-cell Therapy

March 14th 2024
Article

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

The Impact of CAR T-Cell Therapy on Hematological Malignancies

The Impact of CAR T-Cell Therapy on Hematological Malignancies

March 11th 2024
Article

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.